International researchers have been performing what could be very important work in relation to 3D printed medications, with their findings outlined in the recently published ‘Plasticizer-Free 3D Printed Hydrophilic Matrices: Quantitative 3D Surface Texture, Mechanical, Swelling, Erosion, Drug Release, and Pharmacokinetic Studies.’
The focus of their study is hydroxypropyl methyl cellulose (HPMC), a hydrophilic polymer which could have enormous potential for fabrication of matrix tablets. Here, the research team analyzed plasticizer-free 3D printed hydrophilic matrices with drug-loaded filaments, examining their performance level in both in vitro and in vivo applications.
And while pharmaceutical companies worldwide may already be able to manufacture medication in the appropriate dose and shape—sometimes affordably so—with 3D printing they can offer patients what undeniably is the future of medicine with patient-specific treatment. This has already been documented with the FDA approval of Spritam, the first 3D printed epilepsy drug, and much discussion over how such technology will be harnessed in the future with the potential for DIY drugs.
“Although the current methods are common and cost-effective, they offer little opportunity for personalization and on-demand manufacturing as the change in size, shape and dose of a tablet require alterations at each manufacturing step and retooling of tableting machines,” said the researchers. “Consequently, a technology capable of producing dosage forms with a variety of strengths, such as three dimensional (3D) printing, is required to accomplish the personalized therapeutic needs of individuals.”
Previous researchers have tried to create 3D printed medications using a variety of different filaments, and with different composites and hardware. Polymers are an extremely common choice for such medications, with combinations such as plasticizers used to make extrusion easier. Such additions could, however, affect drug absorption negatively. For 3D printing via FDM, the materials must be strong and ‘mechanically robust’ enough to endure the fabrication process. Seam-line issues may arise, as well as problems with too much porosity. To compensate for previously known obstacles, the research team avoided the use of plasticizers. They also tested and evaluated the surface texture, employing both mercury intrusion porosimetry and white light optical profilometry.
“Glipizide which is an anti-diabetic drug of the sulfonylurea class indicated to treat type-2 diabetes was used as a model drug. Glipizide is a weak acid (pKa = 5.9), practically insoluble in water and acid, and is highly permeable (biopharmaceutics classification system, BCS II),” stated the researchers. “It appears to be an effective insulin secretagogue which reaches a peak plasma concentration within 1–3 h after a single oral dose with an elimination half-life of about 2–4 h. Such rapidly absorbed drugs having fast elimination rates with short half-life make it a suitable candidate to be considered for sustained delivery.”
The research team was successful in 3D printing the HPMC materials without using plasticizer.
“Overall, XRD spectra of glipizide and drug loaded HPMC filaments were consistent with the DSC profiles, thus, both methods showed that glipizide has a crystalline structure, whereas HPMC and drug loaded filaments have amorphous nature. This may potentially enhance dissolution but could negatively impact stability,” stated the researchers.
Ultimately, the loaded filaments did produce 3D printed hydrophilic matrices that were all similar in thickness, diameter, and weight; however, the 3D printed surfaces were found to be ‘considerably rougher.’
“… it can be concluded that the viscosity of HPMC has a noticeable impact of the swelling, erosion, HPMC dissolution, drug release and pharmacokinetic properties. The highest viscosity grade (K100M) tends to have a higher degree of swelling, decreased HPMC dissolution, low matrix erosion, decreased drug release and extended drug absorption profile,” stated the researchers. “Overall, this study confirmed the successful fabrication of 3D printed matrix tablets which have functionalities analogous to matrix tablets fabricated using conventional technologies. Moreover, the current study has also demonstrated the usefulness of the FDM technique, providing a simple solution to develop personalized pharmaceutical formulations in a time and cost-effective manner addressing challenges confronted by conventional manufacturing processes.”
What do you think of this news? Let us know your thoughts! Join the discussion of this and other 3D printing topics at 3DPrintBoard.com.[Source / Images: ‘Plasticiser-Free 3D Printed Hydrophilic Matrices: Quantitative 3D Surface Texture, Mechanical, Swelling, Erosion, Drug Release, and Pharmacokinetic Studies’]
You May Also Like
3D Printing News Briefs, September 12, 2020: DSM, MakerOS, Evolve Additive Solutions, & Print Parts Inc.
3D Printing News Briefs runs the gamut today from materials and software to business. First, DSM is announcing a new food-safe 3D printing material, and MakerOS has a new software...
Thanks to New Round, Xometry Raised $193M Total in Funding Since 2013
Maryland-based Xometry, a custom on-demand manufacturing marketplace which recently launched a video interview series and announced a partnership with ExOne to offer metal binder jetting services, has more exciting news to...
3D Printing News Briefs, September 5, 2020
In today’s 3D Printing News Briefs, the former CEO of Carbon has joined the faculty of a prestigious university. Moving on, a 3D printing whiz and Tel Aviv professor has...
3D Printing News Briefs, August 30, 2020: Roboze, BCN3D & CREA3D, 3D Systems, ASTM International
We’re covering 3D printing business stories in today’s 3D Printing News Briefs, including investments, partnerships, industry executives, and annual reports. Federico Faggin, who invented the microprocessor, is investing in Roboze,...
View our broad assortment of in house and third party products.